Clearmind Medicine Inc. Common Shares
Here’s whether Clearmind Medicine Inc. Common Shares (CMND) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 41 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-11.03% over 10 days); weak 1-year return of -98.9%; 3-month momentum negative (-61.0%); rising volume on a downtrend (distribution, 2.73x avg). Currently 99.2% off its 52-week high. Score: -5/7.
CMND is trading below its 200-day MA ($129.84) — a key warning sign the longer-term trend is under pressure. An RSI of 40.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -98.9% compares to +24.4% for SPY (trailed the market by 123.3%). The current 99.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.